Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07536802 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention

Study acronym: AMPACT
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 22, 2026 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study title shortened, about 4 wordsv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.
Trial Details
NCT Number NCT07536802
Lead Sponsor National Institute of Cardiovascular Diseases, Pakistan
Conditions
(from sponsor)		 ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon, Coronary Slow Flow, Acute Myocardial Infarction
Related terms No-Reflow Phenomenon, ST Elevation Myocardial Infarction
Enrollment 1,148 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov